Amgen Gets Romo FOMO
A complete response letter for Amgen 's osteoporosis candidate romosozumab is hardly a surprise. More puzzling is the fact the company is seemingly pushing ahead with the project in spite of worries over serious cardiovascular events.
from Biotech News
0 Comments